LEON E. ROSENBERG TAKES OVER AS CHAIR OF KARO BIO SUCCEEDING PER-OLOF MÅRTENSSON

LEON E. ROSENBERG TAKES OVER AS CHAIR OF KARO BIO SUCCEEDING PER-OLOF MÅRTENSSON

Per-Olof Mårtensson has resigned as chairman of the Board of directors of Karo
Bio for family reasons.  The Board named Leon E. Rosenberg, M.D. as the
company's interim chairman, to serve until the company's shareholders elect a
permanent chairman at the next annual shareholders meeting in April 2008.

Dr. Rosenberg has been a member of the Karo Bio Board since 2000.  From
1991-1998, he served Bristol-Myers Squibb as Chief Scientific officer, and as
Senior Vice-President for Scientific Affairs.  He has also served on the boards
of directors of several other biotechnology companies, and currently chairs the
Board of Hana Biosciences, located in San Francisco, California.  Dr. Rosenberg
is a Professor at Princeton University, and is a member of the U.S. National
Academy of Sciences.

In recognizing Per-Olof Mårtensson's many contributions to Karo Bio, Dr
Rosenberg said "the company owes a huge debt of gratitude to POM for his nearly
20 years of uninterrupted, invaluable service to our company.  The Board will
miss him, and wishes him all good fortune in his personal and professional life
ahead."

For further information, please contact:
Per Olof Wallström, President & Chief Executive Officer 
Telephone: +46 8 608 60 20

Per-Olof Mårtensson 
Telephone: +46 8 608 60 27

Facts about Karo Bio 
Karo Bio is a drug discovery and development company specializing in nuclear
receptors for the development of novel pharmaceuticals with focus on metabolic
diseases. 

The company has expanded from being a drug discovery company by adding in-house
preclinical and clinical development resources and competence for development of
drugs to treat metabolic diseases. The company has a strong project portfolio
with innovative molecules that primarily targets diseases such as diabetes,
atherosclerosis and dyslipidemia. In all of these areas there are significant
market opportunities and a growing need for new pharmaceuticals with new
mechanisms of action. 

In addition to the proprietary projects Karo Bio has two strategic
collaborations with international pharmaceutical companies and one biotech
collaboration for development of innovative therapies for the treatment of
common diseases.

Karo Bio is listed on the OMX Nordic Exchange Stockholm AB since 1998 (Reuters:
KARO.ST). This press release is also available online at: www.karobio.se and
www.newsroom.cision.com